Joseph Galli, chairman and CEO of Haemacure, said: “We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into the clinic in the first quarter of 2009.
This financing significantly reduces the financial risk. All of our time and attention will be focused on execution and getting a green light from the FDA to enter clinical trials.”